NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
總部位於紐約的戰略諮詢公司研究內斯特啟動全球迷幻物質市場研究2035年之前的預測。
Top players featured include known names such as COMPASS Pathways (NASDAQ:CMPS), Silo Pharma (NASDAQ:SILO), Numinus Wellness (OTC:NUMIF), Cybin (NYSE:CYBN), Mind Medicine (MindMed) (NASDAQ:MNMD), PharmaTher Holdings (OTC:PHRRF) and atai Life Sciences (NASDAQ:ATAI); yet also general biotech industry heavyweights like Jazz Pharmaceuticals (NASDAQ:JAZZ), Janssen Pharmaceuticals (NYSE:JNJ) and Pfizer (NYSE:PFE).
頂級球員亮相包括已知名稱，例如指南針路徑(納斯達克：中醫)，思洛製藥(納斯達克：思洛)，努米諾斯健康(場外交易：NUMIF)，Cybin(紐約證券交易所代碼：CYBN)，精神醫學(MindMed)(納斯達克：mnmd)，PharmaTher控股(場外交易：PHRRF)和阿泰生命科學(納斯達克：ATAI)；但也有像這樣的一般生物技術行業重量級企業Jazz製藥公司(納斯達克：爵士)，揚森製藥公司(紐約證券交易所股票代碼：JNJ)和輝瑞公司(紐約證券交易所代碼：PFE)。
The global market's size is predicted to grow at a CAGR of around 14% in the next 12 years, garnering a revenue of $12 billion by the end of 2035, up from 2022's $3 billion.
全球市場的規模預計將以年復合增長率約為14%在未來12年內，到2035年底獲得120億美元的收入，而不是2022年S：30億美元。
See Also: Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
另見：Mindset Pharma以6000萬美元收購大冢邁向下一代精神病學解決方案
Context And Key Takeaways
背景和主要內容
As most pharmaceutical market projections do, the research contemplates the COVID pandemic's effects in terms of a rise in demand for psychedelic drugs to treat mental health issues, either new or enhanced by the situation.
與大多數藥品市場預測一樣，這項研究從治療精神健康問題的迷幻藥物需求上升的角度考慮了COVID大流行的影響，無論是新的還是因這種情況而增強的。
Stress, anxiety and depression spread globally due to uncertainty for the future, jobs and income loss, social isolation and fear of virus transmission, it found.
研究發現，由於未來的不確定性、工作和收入的損失、社會孤立以及對病毒傳播的恐懼，壓力、焦慮和抑鬱在全球蔓延。
The increased demand was exacerbated by the impossibility of accessing traditional forms of therapy due to lockdown. On the other hand, the pandemic reduced production costs, allowing manufacturers to gain higher profit margins and increase the psychedelic drugs market size.
由於封鎖，無法獲得傳統形式的治療，加劇了需求的增加。另一方面，大流行降低生產成本，使製造商獲得更高的利潤率，增加迷幻藥的市場規模。
Recent years' research into psychedelics' potential therapeutic benefits for diverse mental health conditions as well as for general well-being took many pharmaceutical companies and research institutions to increase their focus on developing psychedelic-based treatments.
近年來，關於迷幻劑對不同精神健康狀況以及一般健康狀況的潛在治療益處的研究花了很多時間。製藥公司和研究機構增加他們對開發基於迷幻藥物的治療的關注。
Analysts found that, in 2021, nearly $2 billion were invested in the psychedelics sector, vouching for more R&D and the corresponding costly clinical trials. In the next couple of years, increasing venture capitalists' investment along with more patent filings for psychedelic-related drugs and collaborations between academic institutions and pharmaceutical companies would further boost the market's growth.
分析人士發現，在2021年，近20億美元投資於迷幻藥部門，保證更多的研發和相應的昂貴的臨床試驗。在接下來的幾年裡，增加風險資本家的投資，以及更多迷幻相關藥物的專利申請，以及學術機構和製藥公司之間的合作，將進一步推動市場的增長。
Key points:
要點：
-
The North American market is potentially the one with the largest revenue by the end of 2033. Specifically with PTSD, but also due to the growing prevalence and incidence of depression, anxiety disorders, schizophrenia, eating disorders and addictions (see 2022's staggering numbers.)
-
The Asia Pacific market, for its part, would be the one growing at the highest rate by 2033, following a rise in mental health awareness and "the rising focus" of governments on the improvement of healthcare infrastructure and the increasing prevalence of mental disorders such as depression in the region.
-
In the end-user segment, hospitals would hold the largest revenue by the end of 2033.
-
Other market segmentations include drugs and type; source; and administration routes.
-
這個北美市場有可能是帶有最大的收入到2033年底。尤其是與創傷後應激障礙，但也是由於抑鬱症、焦慮症、精神分裂症、飲食失調和成癮的患病率和發病率不斷上升(見2022是驚人的數位。)
-
這個亞太地區市場，就其本身而言，將是在最高利率到2033年，隨著心理健康意識的提高和各國政府對改善醫療保健基礎設施的“日益關注”，以及該區域抑鬱症等精神障礙的日益普遍。
-
在終端用戶細分市場，醫院將舉行最大的收入到2033年底。
-
其他細分市場包括藥品和類型、來源和給藥途徑。
Into the cannabis industry? Then our imminent Cannabis Capital Conference is where you ought to be! Whether to close your deals or just get acquainted with the sector's best, come join us on Sept. 27-28 in Chicago for our 17th edition. Tickets HERE.
進入大麻行業？那麼我們的大麻之都會議即將召開才是你應該在的地方！無論是完成您的交易，還是僅僅是瞭解行業最好的產品，請於9月9日加入我們。27-28在芝加哥為我們的第17屆。車票在這裡。
Photo: Benzinga edit with photo by chrissmith12 and Bru-nO on Pixabay.
圖片來源：Benzinga編輯圖片由Pixabay上的克裡斯史密斯12和布魯諾。